The evaluation of oxidative stress parameters in breast and colon cancer

Abstract

Our aim in this study was to investigate the relationship between serum ischemia modified albumin (IMA) levels with oxidative stress parameters [protein carbonyl (PCO), advanced protein oxidation products (AOPPs), malondialdehyde (MDA), total nitric oxide (NOx), prooxidant-antioxidant balance (PAB), and ferric reducing of antioxidant power (FRAP)] in breast cancer (BC) and colon cancer (CC). In total, 90 patients undergoing surgical treatment for BC (n = 45) or CC (n = 45) and 35 healthy controls were included in this cross-sectional study. The serum PCO, AOPPs, MDA, NOx, PAB, and IMA levels were all statistically significantly higher in the cancer patients than in the control group. MDA, NOx, and PAB levels were significantly lower in the BC group than in the CC group. FRAP values were statistically significantly lower in both the CC group and the BC group compared to the control. IMA showed a weak positive correlation with CA-19.9 (r = 0.423 P = .007) but a moderate positive correlation with tumor size in the CC group. IMA showed a positive correlation with metastasis, grade, and HER2 and a negative correlation with ER and PR in the BC group. Oxidative stress is a key player in the development of solid malignancies. Cancer development is a multistage process, and oxidative stress caused by the production of ROS/RNS in the breast and colon may predispose individuals to BC and CC. Patients with BC and CC had an impaired oxidative/antioxidant condition that favored oxidative stress. The ROC analysis indicated that IMA sensitivity above 80% could be used as a secondary biomarker in diagnosis.

Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial

“…The observed association of sarcopenia with high plasma MDA at 6-month is consistent with increased MDA levels in sarcopenic elderly compared to their nonsarcopenic counterparts [ 38 , 77 ]. Furthermore, plasma MDA has been suggested as a biomarker of cancer and tumour progression [ 78 – 80 ]. Also, a significant increase was observed in patients undergoing treatment for cervical cancer as compared to pretreatment levels [ 81 ].…”

Ischemia-Modified Albumin: Origins and Clinical Implications

“…Therefore, the antioxidant/oxidative parameters of tumors are prognostically crucial in many types of cancer. These parameters can be assessed via the detection of wellknown oxidative markers of proteins, such as protein carbonyls, advanced oxidation protein products, and IMA [158]. Many investigations have demonstrated that IMA levels significantly increased in different proliferative diseases (Table 5).…”

“…According to the ROC analysis, IMA has sensitivity above 80% as an auxiliary biomarker in the diagnosis of such diseases as breast and colon cancer [158]. It can be effective in demonstrating hypoxia in patients with acute leukemia [166] and used as an additional indicator for the prognosis of the myelodysplastic syndrome [167].…”

Diet‐derived ergothioneine induces necroptosis in colorectal cancer cells by activating the SIRT3/MLKL pathway

“…Indeed, differences in tumour microenvironment might translate into distinct responsiveness to cell death. Persistent oxidative stress is a common feature of CRC cells which is known to be exacerbated by some natural antioxidant [58,59]. It is undoubtedly intriguing how the antioxidant Egt induces ROS, which itself seem to fail to quench completely, causing CRC cell death.…”